Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.67 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.65 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 8/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL847081 | 1.00 | HCAR2 (0.67) | HCAR2KEAP1NFE2L2MAPTATM | |
| Diethyl Maleate SCHEMBL1997508 | 1.00 | HCAR2 (0.67) | HCAR2KEAP1NFE2L2MAPTATM | |
| Diethyl Maleate SCHEMBL28185444 | 1.00 | HCAR2 (0.67) | HCAR2KEAP1NFE2L2MAPTATM | |
| Diethyl Maleate SCHEMBL28318001 | 1.00 | HCAR2 (0.67) | HCAR2KEAP1NFE2L2MAPTATM | |
| SCHEMBL847082 | 1.00 | HCAR2 (0.67) | HCAR2KEAP1NFE2L2MAPTATM | |
| SCHEMBL4179973 | 0.93 | HCAR2 (0.59) | HCAR2KEAP1NFE2L2MAPTATM | |
| Ethyl Fumarate SCHEMBL4179975 | 0.91 | HCAR2 (0.83) | HCAR2KEAP1NFE2L2MAPTATM | |
| Ethyl Fumarate SCHEMBL4179969 | 0.91 | HCAR2 (0.83) | HCAR2KEAP1NFE2L2MAPTATM | |
| Dimethyl Maleate SCHEMBL28089786 | 0.91 | HCAR2 (0.57) | HCAR2KEAP1NFE2L2MAPTATM | |
| Ethyl Fumarate SCHEMBL28185445 | 0.91 | HCAR2 (0.83) | HCAR2KEAP1NFE2L2MAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057770-A1 | Monomethylfumarate Prodrug Compositions | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-02-20 | — | — | US | claimed |
| WO-2022186442-A1 | PRESSURE-SENSITIVE ADHESIVE COMPOSITION WITH EXCELLENT PIGMENT DISPERSIBILITY, AND PRESSURE-SENSITIVE ADHESIVE SHEET USING SAME | 주식회사 켐코 | 2022-09-09 | — | — | WO | claimed |
| US-11382889-B2 | NRF2 activators for the prevention and/or treatment of axonal degeneration | INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL) (ES) | 2022-07-12 | — | — | US | claimed |
| US-20220105064-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | BIOGEN SWISS MFG GMBH (CH) | 2022-04-07 | — | — | US | claimed |
| US-20220079884-A1 | PHARMACEUTICAL FORMULATION COMPRISING ONE OR MORE FUMARIC ACID ESTERS IN AN EROSION MATRIX | BIOGEN SWISS MFG GMBH (CH) | 2022-03-17 | — | — | US | claimed |
| US-11229619-B2 | Controlled release pharmaceutical compositions comprising a fumaric acid ester | BIOGEN SWISS MANUFACTURING GMBH (CH) | 2022-01-25 | — | — | US | claimed |
| US-20190321322-A1 | NRF2 ACTIVATORS FOR THE PREVENTION AND/OR TREATMENT OF AXONAL DEGENERATION | INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (ES) | 2019-10-24 | — | — | US | claimed |
| US-20190201368-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | BIOGEN SWISS MANUFACTURING GMBH (CH) | 2019-07-04 | — | — | US | claimed |
| US-20190117613-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | BIOGEN SWISS MANUFACTURING GMBH (CH) | 2019-04-25 | — | — | US | claimed |
| CN-109044985-A | Pharmaceutical preparation comprising one of corrosion skeleton or a variety of fumarates | 前进制药知识产权有限公司 | 2018-12-21 | — | — | CN | claimed |
| WO-2007042034-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | ADITECH PHARMA AB (SE) | 2007-04-19 | — | — | WO | claimed |
| EP-1248606-B1 | USE OF FUMARIC ACID DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES | FUMAPHARM AG (CH) | 2006-06-14 | — | — | EP | claimed |
| WO-2006037342-A2 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | ADITECH PHARMA AB (SE) | 2006-04-13 | — | — | WO | claimed |
| EP-1409566-A4 | PHOTOCROSSLINKING OF DIETHYL FUMARATE/POLY(PROPYLENE FUMARATE) BIOMATERIALS | UNIV WM MARSH RICE (US) | 2005-02-16 | — | — | EP | claimed |
| EP-1409566-A2 | PHOTOCROSSLINKING OF DIETHYL FUMARATE/POLY(PROPYLENE FUMARATE) BIOMATERIALS | Wm. MARSH RICE UNIVERSITY (US) | 2004-04-21 | — | — | EP | claimed |
| US-20030032733-A1 | Photocrosslinking of diethyl fumarate/poly (propylene fumarate) biomaterials | WM. MARSH RICE UNIVERSITY (US) | 2003-02-13 | — | — | US | claimed |
| WO-2003002490-A2 | PHOTOCROSSLINKING OF DIETHYL FUMARATE/POLY(PROPYLENE FUMARATE) BIOMATERIALS | WM. MARSH RICE UNIVERSITY (US) | 2003-01-09 | — | — | WO | claimed |
| EP-1248606-A1 | USE OF FUMARIC ACID DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES | Fumapharm AG (CH) | 2002-10-16 | — | — | EP | claimed |
| WO-2002055066-A1 | FUMARIC ACID DERIVATIVES AS NF-KAPPA-B INHIBITORS | FUMAPHARM AG (CH) | 2002-07-18 | — | — | WO | claimed |
| WO-2001051047-A1 | USE OF FUMARIC ACID DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES | FUMAPHARM AG (CH) | 2001-07-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250057770-A1 | Monomethylfumarate Prodrug Compositions | DHFR, FPGS, G6PD | HCAR2 494/4885KEAP1 738/4885NFE2L2 1407/4885 |
| US-20190321322-A1 | NRF2 ACTIVATORS FOR THE PREVENTION AND/OR TREATMENT OF AXONAL DEGENERATION | KEAP1, NFE2L2, GSK3A | HCAR2 1425/4885KEAP1 1/4885NFE2L2 2/4885 |
| US-11382889-B2 | NRF2 activators for the prevention and/or treatment of axonal degeneration | KEAP1, NFE2L2, GSK3A | HCAR2 1425/4885KEAP1 1/4885NFE2L2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.